Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS

NCT01887561 is registered in ClinicalTrials.gov with Kanto CML Study Group as lead sponsor.

NCT NCT01887561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01887561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS
Lead sponsor
Kanto CML Study Group
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2012
Completion date
Not reported
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelogenous leukemia, chronic, chronic phase